Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTS Chemical Industries

This article was originally published in The Tan Sheet

Executive Summary

Company withdraws citizen petition requesting GRAS status for use of echinacea extract as binding agent in certain solid-dosage form drugs, FDA acknowledges in Oct. 3 letter to Israeli pharmaceutical firm's New Jersey-based consultant. CTS filed a petition in September 2000 proposing use of the extract, in amounts of 3 mg-30 mg per dosage unit, in cough/cold remedies, antidiarrheal agents, analgesics, antibiotics (1"The Tan Sheet" Sept. 18, 2000, p. 3)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS093163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel